ImmunOs Gets Cash Injection To Advance Potential First-In-Class Cancer Agent
Swiss Biotech Banks $74m
It has proved tricky of late for European biotechs to raise funds, but Switzerland's ImmunOs has gathered a group of top-tier US and European investors to help push lead asset IOS-1002, a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen, towards the clinic.
